Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis (Q77906160)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9918907%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

title

Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9918907%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

1 reference

Schneider AW

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9918907%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

Kalk JF

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9918907%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

Klein CP

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9918907%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

language of work or name

English

0 references

publication date

1 February 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9918907%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9918907%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9918907%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9918907%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

page(s)

334-339

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9918907%20AND%20SRC:MED&resulttype=core&format=json

Liver function and pharmacological considerations in pathogenesis and treatment of portal hypertension

9 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290203

7 January 2021

Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. Franco-Italian Multic

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290203

7 January 2021

A randomized controlled study of propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a final report

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290203

7 January 2021

Effects of Propranolol on Azygos Venous Blood Flow and Hepatic and Systemic Hemodynamics in Cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290203

7 January 2021

Short-term effects of propranolol on portal venous pressure

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290203

7 January 2021

Propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis: long-term hemodynamic and renal effects

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290203

7 January 2021

Reduction of portal pressure by isosorbide-5-mononitrate in patients with cirrhosis. Effects on splanchnic and systemic hemodynamics and liver function.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290203

7 January 2021

Propranolol compared with propranolol plus isosorbide dinitrate in portal-hypertensive patients: long-term hemodynamic and renal effects.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290203

7 January 2021

Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290203

7 January 2021

Angiotensin receptors and their antagonists

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290203

7 January 2021

Fat-storing cells as liver-specific pericytes. Spatial dynamics of agonist-stimulated intracellular calcium transients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290203

7 January 2021

The cellular pathogenesis of portal hypertension: stellate cell contractility, endothelin, and nitric oxide

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290203

7 January 2021

Hypotensive agents and pressor substances. The effect of epinephrine, norepinephrine, angiotensin II, and others on the secretory rate of aldosterone in man

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290203

7 January 2021

Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290203

7 January 2021

Hepatic venous pressure measurement: an old test as a new prognostic marker in cirrhosis?

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290203

7 January 2021

Transection of the oesophagus for bleeding oesophageal varices

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290203

7 January 2021

Sclerotherapy of bleeding oesophageal varices by means of endoscopy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290203

7 January 2021

[Spironolactone in the treatment of portal hypertension in liver cirrhosis. A new therapeutic principle?]

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290203

7 January 2021

The angiotensin II receptor of rabbit liver: characterization in isolated hepatocytes and effect of GTP

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290203

7 January 2021

Effect of angiotensin-II blockade on systemic and hepatic haemodynamics and on the renin-angiotensin-aldosterone system in cirrhosis with ascites.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290203

7 January 2021

Angiotensin receptor antagonists: focus on losartan

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290203

7 January 2021

Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290203

7 January 2021

Hemodynamic effects of a clonidine-induced decrease in sympathetic tone in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290203

7 January 2021

Acute haemodynamic changes after oral carvedilol, a vasodilating beta-blocker, in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290203

7 January 2021

Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290203

7 January 2021

Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290203

7 January 2021

Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290203

7 January 2021

Portal pressure, renal function and hormonal profile after acute and chronic captopril treatment in cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290203

7 January 2021

Identifiers

DOI

10.1002/HEP.510290203

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9918907%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9918907%20AND%20SRC:MED&resulttype=core&format=json